Daily BriefsThematic (Sector/Industry)

Daily Brief Thematic (Sector/Industry): Ohayo Japan | A Big Week for the BoJ and more

In today’s briefing:

  • Ohayo Japan | A Big Week for the BoJ
  • China BIG-3 Mainland Airlines Traffic 18% Higher than 2019!
  • Important New Policy for China’s Innovative Drugs – The Game Rule Is About to Change Radically
  • GEMWeekly (15 Mar 2024): China, South Korea, India Macro; TSMC, Samsung Electronics, Xiaomi, Alibaba


Ohayo Japan | A Big Week for the BoJ

By Mark Chadwick

  • Last week, most major indices experienced slight declines, with the SPX down by 0.1% and the Nasdaq by 0.7%, on higher bond yields.
  • Looking ahead to this week, there are several key events that could drive market movement: both the Fed and BOJ hold monetary policy meetings. Elsewhere, focus on Nvidia GPU Conference
  • Nissan (7201) and Honda (7267), facing challenges in competing with rivals like Tesla in electric vehicle (EV) investments, are considering a partnership to collaborate on EVs

China BIG-3 Mainland Airlines Traffic 18% Higher than 2019!

By Mohshin Aziz

  • In aggregate, traffic among the Big-3 Chinese airlines was up 67% YoY in February and +18% vs 2019. Incontestable proof that China has regained its air travel mojo. 
  • Published March schedules show total implied capacity is 31% higher YoY and 9% higher than 2019 levels. This is driven by domestic travel, international remains depressed. 
  • Driven by domestic travel, international remains depressed. POSITIVE for China Eastern and other North Asian carriers that provide the missing North America link. 

Important New Policy for China’s Innovative Drugs – The Game Rule Is About to Change Radically

By Xinyao (Criss) Wang

  • A document titled “Soliciting Opinions on the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain” attracted widespread attention, which is significantly different from past policies. 
  • Restrictions on payment end and deteriorating investment and financing situations will be improved, marking a new starting point for China’s innovative drug business. We have reasons to start being optimistic.
  • If approved and implemented, it would be a significant reversal of the previous expectation and investment logic of innovative drugs. So, investors should not overlook the importance of this document.

GEMWeekly (15 Mar 2024): China, South Korea, India Macro; TSMC, Samsung Electronics, Xiaomi, Alibaba

By Wium Malan, CFA


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars